Revance Therapeutics, Inc. (RVNC)

NASDAQ: RVNC · IEX Real-Time Price · USD

2.420

-0.150 (-5.84%)

At close: Jul 2, 2024, 4:00 PM

2.479

+0.059 (2.44%)

After-hours: Jul 2, 2024, 6:27 PM EDT

Revance Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Net Income	-323.99	-356.42	-281.31	-282.09	-159.43	Upgrade
Depreciation & Amortization	13.69	39.15	19.85	10.25	2.91	Upgrade
Share-Based Compensation	47.81	52.34	43.43	36.45	17.92	Upgrade
Other Operating Activities	45.91	71.39	-3.52	56.88	32.44	Upgrade
Operating Cash Flow	-216.58	-193.55	-221.54	-178.5	-106.16	Upgrade
Capital Expenditures	-6.89	-3.21	-10.38	-4.1	-3.23	Upgrade
Acquisitions	0	0	0	-0.82	0	Upgrade
Change in Investments	116.63	-135.59	-19.29	17.17	-14.36	Upgrade
Other Investing Activities	-	-	-	-0.12	-	Upgrade
Investing Cash Flow	109.74	-138.8	-29.67	12.13	-17.59	Upgrade
Share Issuance / Repurchase	115.47	252.83	38.39	90.84	223.78	Upgrade
Debt Issued / Paid	29.31	85.01	-0.34	277.95	0	Upgrade
Other Financing Activities	-8.22	-6.15	-8.19	-37.31	-2.12	Upgrade
Financing Cash Flow	136.57	331.69	29.87	331.48	221.66	Upgrade
Net Cash Flow	29.73	-0.65	-221.33	165.11	97.9	Upgrade
Free Cash Flow	-223.46	-196.76	-231.91	-182.6	-109.39	Upgrade
Free Cash Flow Margin	-95.48%	-148.42%	-298.10%	-1191.52%	-26486.92%	Upgrade
Free Cash Flow Per Share	-2.64	-2.71	-3.44	-3.15	-2.52	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).